MarginsXMarginsX
Home › Markets › Health Care › CELU

Celularity Inc. (CELU)

CELU trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.6191
-1.75% on the day
Market cap
$20.1M
Nano cap
Revenue · 2025
$26.6M
-51.0% on 2024
Net income · 2025
-$91.7M
-345.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1752828/000149315226020424/0001493152-26-020424-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCELU on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2019
SEC CIK0001752828
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$26.6M
Net income-$91.7M
Operating income-$61.3M
Net margin-345.4%
Operating margin-230.9%
Revenue growth-51.0%
Cash$6.2M
Total assets$107.3M
P/E (computed)Net income was not positive
P/S (computed)0.8×

Warning signs

Cash runway
0.8 months
$586K cash at June 30, 2026
Share count, 1 year
+14.5%
2025-11-14 to 2026-10-19 · +69.9% over 3 years
Going-concern doubt
Yes
10-Q filed October 20, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Management has evaluated the Company's current financial position, liquidity, capital resources, and projected cash flows and has determined that there is substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-10-20
Cash and burn$586K cash; operating cash flow -$2.2M a quarter.Report 2026-06-30
Shares outstanding32,450,679 (2026-10-19); 28,328,880 a year earlier; 190,948,190 three years earlier. 3y figure adjusted for split (1-for-10 overall).Cover page 2026-10-19
Reverse splits, 3 years1; latest 1-for-10 on 2024-02-29Source 2024-02-29
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-07-29
Delisting25-NSE filed25-NSE 2026-07-22
AuditorEisnerAmper LLP, Iselin, New Jersey, United StatesPCAOB Form AP 2026-05-01
Late filings, 12 months3 NT noticesNT 10-Q 2026-08-14
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$5.4M$706K-$1.1M$586KNo debt tags$18.7M10-Q 2026-10-20
Q1 2026
2026-03-31
$3.8M$874K$1.4M$368KNo debt tags$19.0M10-Q 2026-09-29
Q4 2025
2025-12-31
$4.1M-$24.4M-$5.1M$6.2M$33.8M$26.6M10-K 2026-04-30
Q3 2025
2025-09-30
$5.3M-$23.1M-$4.2M$120K$35.7M$40.6M10-Q 2025-11-14
Q2 2025
2025-06-30
$5.7M-$24.5M-$999K$863K$6.3M$44.6M10-Q 2026-10-20
Q1 2025
2025-03-31
$11.4M-$19.8M-$3.0M$293K$6.3M$51.0M10-Q 2026-09-29
Q4 2024
2024-12-31
$18.1M-$13.3M$1.6M$738KNo debt tags$54.2M10-K 2026-04-30
Q3 2024
2024-09-30
$9.3M-$16.1M-$144K$133K$42.6M$48.2M10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-01-08
Latest annual report10-K/A2026-10-20
Latest quarterly / interim10-Q2026-10-20
Latest current report8-K2026-10-29
Latest proxyDEFA14A2026-11-10

Source: SEC EDGAR submissions feed, 564 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-17.1%
1 month-55.6%
3 months-9.4%
Year to date-43.2%
1 year-60.4%
From 52-week high-70.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
SHPHShuttle Pharmaceuticals Holdings Inc.$4.24-6.40%$20.2M
AYTUAytu BioPharma Inc.$1.82+1.68%$19.8M
IGCIGC Pharma Inc.$0.1750-0.57%$20.4M
CPHIChina Pharma Holdings Inc.$0.4800-7.35%$20.7M
TXMDTherapeuticsMD Inc.$1.81-3.21%$20.9M
ATOSAtossa Therapeutics Inc.$1.93-1.53%$19.3M
COCPCocrystal Pharma Inc.$0.9777-0.24%$18.8M
LPCNLipocine Inc.$1.66-2.92%$18.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier